ALEXANDRIA, Va., Sept. 3 -- United States Patent no. 12,404,338, issued on Sept. 2.
"Anti CD30 chimeric antigen receptor and its use" was invented by Markus Chmielewski (Cologne, Germany), Andreas Hombach (Cologne, Germany) and Hinrich Abken (Cologne, Germany).
According to the abstract* released by the U.S. Patent & Trademark Office: "In a first aspect, the present disclosure relates to genetically modified T-cells having a chimeric antigen receptor for use in adoptive cell therapy for treating CD30+ cancer in a subject need thereof. In particular, the present disclosure relates to a T-cell containing a specific chimeric antigen receptor being toxic to CD30+cancer cells while being non-toxic to CD30+ non-cancer cells. In a further aspect...